Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Lymphoma, Follicular 10Sarcoma 6Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell 4Rhabdoid Tumor 3Prostatic Neoplasms 3Wilms Tumor 2Sarcoma, Synovial 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Urinary Bladder Neoplasms 1Tertiary Lymphoid Structures 1Solid Tumor 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Neoplasms 1

Interventions

pembrolizumab 6Injections 6senaparib 4toripalimab 3tislelizumab 3Bevacizumab 3sintilimab 2Technetium 2Specimen Handling 2Nivolumab 2Ipilimumab 2Fluorodeoxyglucose F18 2Carboplatin 2Blood Specimen Collection 2zimberelimab 1tumor-cells apoptosis factor, human 1tazemetostat 1spartalizumab 1sacituzumab govitecan 1rucaparib 1osimertinib 1olaparib 1etoposide phosphate 1enzalutamide 1envafolimab 1cemiplimab 1cedazuridine 1atezolizumab 1WW Domain-Containing Oxidoreductase 1Ultrasonography, Doppler 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumor × tazemetostat × 1 year × Clear all
NCT05023655 2026-03-17

Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

Prisma Health-Upstate

Phase 2 Terminated
20 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡